Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

BusinessWire_EN 
0 0 09.11.21
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
 

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:

  • Barclays Gene Editing & Gene Therapy Summit
    Date: Monday, November 15th at 10:30 a.m. Eastern Time
  • Stifel 2021 Virtual Healthcare Conference
    Date: Monday, November 15th at 3:20 p.m. Eastern Time
  • Jefferies London Healthcare Conference
    Date: Tuesday, November 16th at 8:40 a.m. Eastern Time

For presentations and fireside chats that are webcast live, an access link will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentations will also be available on the Sangamo Therapeutics website after the event.

About Sangamo Therapeutics

Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist. For more information about Sangamo, visit www.sangamo.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005592/en/

Sangamo Therapeutics Inc. Stock

€0.52
1.140%
There is an upward development for Sangamo Therapeutics Inc. compared to yesterday, with an increase of €0.006 (1.140%).
With 11 Buy predictions and 12 Sell predictions the community is currently undecided on Sangamo Therapeutics Inc..
However, we have a potential of 473.83% for Sangamo Therapeutics Inc. as the target price of 3 € is above the current price of 0.52 €.
Show more
Like: 0
Share
BusinessWire_EN 
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments

Not a member yet? Sign up for free!